Medicaid Cost of Incomplete Payment Eats Into Physician Reimbursement
One-quarter of Medicaid claims result in a denial of payment for at least one service included in the claim compared with just 7.3% of claims submitted to Medicare and 4.8% of claims submitted to commercial insurers
One-quarter of Medicaid claims result in a denial of payment for at least one service included in the claim compared with just 7.3% of claims submitted to Medicare and 4.8% of claims submitted to commercial insurers, according to National Bureau of Economic Research study published in July.
Abe Dunn, Ph.D., the study’s lead author and an economist in the Bureau of Economic Analysis in the Department of Commerce, and his colleagues set out to examine and quantify the “administrative frictions” in claims for medical services.
They came up with a statistic they call the cost of incomplete payments (CIP), which comprises forgone revenues when a claim is denied and the costs associated with the back-and-forth of trying to get payment. Their research shows that CIP eats up 17.4% of the contracted fee of a typical Medicaid visit, 5% of a Medicare fee and 2.8% of commercial insurance fee.
“These are significant losses — especially for Medicaid, which offers physicians much lower reimbursement rates than other insurers in the first place,” they wrote. Medicaid’s high CIP is, they argue, tantamount to a tax on physician revenues.
Dunn and his co-authors say their research opens up another avenue to reducing inequality in healthcare.
“Without expanding eligibility or raising reimbursement, improving Medicaid claims administration could help make healthcare for low-income Americans more similar to Medicare or employer-sponsored healthcare,” they said.
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
